Dianne C. Whitfield - Nov 29, 2022 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Role
Chief Human Resources Officer
Signature
/s/ Leonard M. Greenstein, Attorney-in-Fact
Stock symbol
TARS
Transactions as of
Nov 29, 2022
Transactions value $
-$39,017
Form type
4
Date filed
12/1/2022, 07:09 PM
Previous filing
Mar 11, 2022
Next filing
Dec 6, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TARS Common Stock Options Exercise $0 +10.3K +519.56% $0.00 12.2K Nov 29, 2022 Direct F1, F2
transaction TARS Common Stock Sale -$19.5K -1.18K -9.67% $16.50 11K Nov 30, 2022 Direct F3
transaction TARS Common Stock Sale -$19.5K -1.17K -10.55% $16.75 9.88K Dec 1, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TARS Restricted Stock Units Options Exercise $0 -10.3K -30% $0.00 23.9K Nov 29, 2022 Common Stock 10.3K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Reporting Person received restricted stock units ("RSUs") which represent a contingent right to receive one share of Issuer's Common Stock for each RSU. This reported transaction represents the settlement of RSUs vested as of November 29, 2022.
F2 Includes 862 shares acquired under the Issuer's employee stock purchase plan on December 31, 2021, and includes 1,111 shares acquired under the Issuer's employee stock purchase plan on June 30, 2022.
F3 The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4 RSU granted under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. The RSUs will vest 30% on November 29, 2022, and 70% on November 29, 2023, subject to the Reporting Person's continuous service.